Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy in Males With Classic Fabry Disease Who Have Never Received Any Treatment

NCT06114329 is registered in ClinicalTrials.gov with AceLink Therapeutics, Inc. as lead sponsor.

NCT NCT06114329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06114329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy in Males With Classic Fabry Disease Who Have Never Received Any Treatment
Lead sponsor
AceLink Therapeutics, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 25, 2023
Completion date
June 30, 2026
Enrollment
16 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease